{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T06:07:22Z","timestamp":1790489242987,"version":"4.1.0"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2010,5,22]],"date-time":"2010-05-22T00:00:00Z","timestamp":1274486400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1007\/s00415-010-5591-7","type":"journal-article","created":{"date-parts":[[2010,5,20]],"date-time":"2010-05-20T23:44:14Z","timestamp":1274399054000},"page":"1421-1431","source":"Crossref","is-referenced-by-count":81,"title":["Neurological adverse events associated with anti-tumor necrosis factor alpha treatment"],"prefix":"10.1007","volume":"257","author":[{"given":"Antonio G.","family":"Tristano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,5,22]]},"reference":[{"issue":"Suppl. 1","key":"5591_CR1","doi-asserted-by":"crossref","first-page":"I32","DOI":"10.1136\/ard.58.2008.i32","volume":"58","author":"G Kollias","year":"1999","unstructured":"Kollias G, Douni E, Kassiotis G, Kontoyiannis D (1999) The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Ann Rheum Dis 58(Suppl. 1):I32\u2013I39","journal-title":"Ann Rheum Dis"},{"key":"5591_CR2","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/mus.20924","volume":"37","author":"JP Stubgen","year":"2008","unstructured":"Stubgen JP (2008) Tumor necrosis factor-\u03b1 antagonists and neuropathy. Muscle Nerve 37:282\u2013292","journal-title":"Muscle Nerve"},{"key":"5591_CR3","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0923-2494(97)87239-2","volume":"148","author":"A Cope","year":"1997","unstructured":"Cope A, Ettinger R, McDevitt H (1997) The role of TNF-\u03b1 and related cytokines in the development and function of the autoreactive T-cell repertoire. Res Immunol 148:307\u2013312","journal-title":"Res Immunol"},{"issue":"suppl 1","key":"5591_CR4","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/ard.58.2008.i32","volume":"58","author":"G Kollias","year":"1999","unstructured":"Kollias G, Douni E, Kassiotis G, Kontoyiannis D (1999) The role of tumor necrosis factor and receptors in models of multi organ inflammation, rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. Ann Rheum Dis 58(suppl 1):32\u201339","journal-title":"Ann Rheum Dis"},{"key":"5591_CR5","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1002\/1529-0131(200109)44:9<1977::AID-ART345>3.0.CO;2-6","volume":"44","author":"WH Robinson","year":"2001","unstructured":"Robinson WH, Genovese MC, Moreland LW (2001) Demyelinating and neurologic events reported in association with tumor necrosis factor \u03b1 antagonism. Arthritis Rheum 44:1977\u20131983","journal-title":"Arthritis Rheum"},{"key":"5591_CR6","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1177\/135245859600100619","volume":"1","author":"R Hohlfeld","year":"1996","unstructured":"Hohlfeld R (1996) Inhibitors of tumor necrosis factor-alpha: promising agents for the treatment of multiple sclerosis? Mult Scler 1:376\u2013378","journal-title":"Mult Scler"},{"key":"5591_CR7","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/377348a0","volume":"377","author":"L Zheng","year":"1995","unstructured":"Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH, Lenardo MJ (1995) Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 377:348\u2013351","journal-title":"Nature"},{"key":"5591_CR8","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1517\/14656566.2.7.1137","volume":"1","author":"A Alldred","year":"2001","unstructured":"Alldred A (2001) Etanercept in rheumatoid arthritis. Expert Opin Pharmacother 1:1137\u20131148","journal-title":"Expert Opin Pharmacother"},{"key":"5591_CR9","unstructured":"Enbrel (etanercept) (2007) Current prescribing information. In: Physicians\u2019 desk reference. Thompson, Montvale, pp 584\u2013591"},{"key":"5591_CR10","unstructured":"Humira (adalimumab) (2007) Current prescribing information. In: Physicians\u2019 desk reference. Thompson, Montvale, pp 466\u2013471"},{"key":"5591_CR11","unstructured":"Remicade (infliximab) (2007) Current prescribing information. In: Physicians\u2019 desk reference. Thompson, Montvale, pp 971\u2013979"},{"issue":"3","key":"5591_CR12","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.autrev.2009.10.003","volume":"9","author":"M Ramos-Casals","year":"2010","unstructured":"Ramos-Casals M, Roberto-Perez-Alvarez, Diaz-Lagares C, Cuadrado MJ, Khamashta MA et al (2010) Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev 9(3):188\u2013193","journal-title":"Autoimmun Rev"},{"issue":"11","key":"5591_CR13","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0025-6196(11)60668-X","volume":"84","author":"DA Wetter","year":"2009","unstructured":"Wetter DA, Davis MD (2009) Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc 84(11):979\u2013984","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"5591_CR14","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1097\/SMJ.0b013e3181bb554c","volume":"102","author":"J Borr\u00e1s-Blasco","year":"2009","unstructured":"Borr\u00e1s-Blasco J, Navarro-Ruiz A, Borr\u00e1s C, Caster\u00e1 E (2009) Adverse cutaneous reactions induced by TNF-alpha antagonist therapy. South Med J 102(11):1133\u20131140","journal-title":"South Med J"},{"issue":"4","key":"5591_CR15","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000049024","volume":"9","author":"P Ghezzi","year":"2001","unstructured":"Ghezzi P, Mennini T (2001) Tumor necrosis factor and motoneural degeneration: an open problem. Neuroimmunomodulation 9(4):178\u2013182","journal-title":"Neuroimmunomodulation"},{"key":"5591_CR16","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1084\/jem.185.9.1573","volume":"185","author":"AP Cope","year":"1997","unstructured":"Cope AP, Liblau RS, Yang XD, Congia M, Laudanna C, Schreiber RD (1997) Chronic tumor necrosis factor alter T cell responses by attenuating T cell receptor signaling. J Exp Med 185:1573\u20131584","journal-title":"J Exp Med"},{"key":"5591_CR17","first-page":"414","volume-title":"Cytokine Reference","author":"BB Aggarwal","year":"2000","unstructured":"Aggarwal BB, Samanta A, Feldmann M (2000) TNF\u03b1. In: Oppenheim JJaFM (ed) Cytokine Reference. Academic Press, London, pp 414\u2013434"},{"key":"5591_CR18","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H","volume":"50","author":"HT Idriss","year":"2000","unstructured":"Idriss HT, Naismith J (2000) TNF alpha and the TNF receptor superfamily: structure-function relationship(s). Microsc Res Tech 50:184\u2013195","journal-title":"Microsc Res Tech"},{"key":"5591_CR19","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0898-6568(01)00262-5","volume":"14","author":"DJ MacEwan","year":"2002","unstructured":"MacEwan DJ (2002) TNF receptor subtype signalling: differences and cellular consequences. Cell Signal 14:477\u2013492","journal-title":"Cell Signal"},{"key":"5591_CR20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1742-2094-5-45","volume":"5","author":"MK McCoy","year":"2008","unstructured":"McCoy MK, Tansey MG (2008) TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation 5:45","journal-title":"J Neuroinflammation"},{"key":"5591_CR21","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/385729a0","volume":"385","author":"RA Black","year":"1997","unstructured":"Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF et al (1997) A metalloproteinase disintegrin that releases tumour-necrosis factor-\u03b1 from cells. Nature 385:729\u2013733","journal-title":"Nature"},{"key":"5591_CR22","doi-asserted-by":"crossref","first-page":"6348","DOI":"10.1073\/pnas.86.16.6348","volume":"86","author":"AP Lieberman","year":"1989","unstructured":"Lieberman AP, Pitha PM, Shin HS, Shin ML (1989) Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus. Proc Natl Acad Sci USA 86:6348\u20136352","journal-title":"Proc Natl Acad Sci USA"},{"key":"5591_CR23","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/sj.mp.4000227","volume":"2","author":"MC Morganti-Kossman","year":"1997","unstructured":"Morganti-Kossman MC, Lenzlinger PM, Hans V, Stahel P, Csuka E, Ammann E et al (1997) Production of cytokines following brain injury: beneficial and deleterious for the damaged tissue. Mol Psychiatry 2:133\u2013136","journal-title":"Mol Psychiatry"},{"key":"5591_CR24","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1093\/hmg\/ddi178","volume":"14","author":"CY Chung","year":"2005","unstructured":"Chung CY, Seo H, Sonntag KC, Brooks A, Lin L, Isacson O (2005) Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. Hum Mol Genet 14:1709\u20131725","journal-title":"Hum Mol Genet"},{"key":"5591_CR25","first-page":"208","volume":"154","author":"A Creange","year":"1998","unstructured":"Creange A, Lefaucheur JP, Authier FJ, Gherardi RK (1998) Cytokines and peripheral neuropathies. Rev Neurol 154:208\u2013216","journal-title":"Rev Neurol"},{"key":"5591_CR26","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s004010050765","volume":"95","author":"N Oka","year":"1998","unstructured":"Oka N, Akiguchi I, Kawasaki T, Mizutani K, Satoi H, Kimura J (1998) Tumor necrosis factor-alpha in peripheral nerve lesions. Acta Neuropathol 95:57\u201362","journal-title":"Acta Neuropathol"},{"key":"5591_CR27","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1073\/pnas.95.2.570","volume":"95","author":"M Grell","year":"1998","unstructured":"Grell M, Wajant H, Zimmermann G, Scheurich P (1998) The type 1 receptor (CD1 20a) is the high-affinity receptor for soluble tumor necrosis factor. Proc Natl Acad Sci USA 95:570\u2013575","journal-title":"Proc Natl Acad Sci USA"},{"key":"5591_CR28","first-page":"8","volume":"47","author":"M Grell","year":"1995","unstructured":"Grell M (1995) Tumor necrosis factor (TNF) receptors in cellular signaling of soluble and membrane-expressed TNF. J Inflamm 47:8\u201317","journal-title":"J Inflamm"},{"issue":"5","key":"5591_CR29","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrc2628","volume":"9","author":"F Balkwill","year":"2009","unstructured":"Balkwill F (2009) Tumor necrosis factor and cancer. Nat Rev Cancer 9(5):361\u2013371","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"5591_CR30","first-page":"159","volume":"26","author":"R Ihnatko","year":"2007","unstructured":"Ihnatko R, Kubes M (2007) TNF signaling: early events and phosphorylation. Gen Physiol Biophys 26(3):159\u2013167","journal-title":"Gen Physiol Biophys"},{"issue":"25","key":"5591_CR31","doi-asserted-by":"crossref","first-page":"18107","DOI":"10.1074\/jbc.274.25.18107","volume":"274","author":"E Haas","year":"1999","unstructured":"Haas E, Grell M, Wajant H, Scheurich P (1999) Continuous autotropic signaling by membrane expressed tumor necrosis factor. J Biol Chem 274(25):18107\u201318112","journal-title":"J Biol Chem"},{"issue":"5","key":"5591_CR32","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.4049\/jimmunol.158.5.2398","volume":"158","author":"T Weiss","year":"1997","unstructured":"Weiss T, Grell M, Hessabi B, Bourteele S, M\u00fcller G, Scheurich P et al (1997) Enhancement of TNF receptor p60-mediated cytotoxicity by TNF receptor p80: requirement of the TNF receptor-associated factor-2 binding site. J Immunol 158(5):2398\u20132404","journal-title":"J Immunol"},{"issue":"4","key":"5591_CR33","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2174\/1566524043360636","volume":"4","author":"MH Holtmann","year":"2004","unstructured":"Holtmann MH, Neurath MF (2004) Differential TNF-signaling in chronic inflammatory disorders. Curr Mol Med 4(4):439\u2013444","journal-title":"Curr Mol Med"},{"key":"5591_CR34","first-page":"152","volume":"45","author":"E Pocsik","year":"1995","unstructured":"Pocsik E, Duda E, Wallach D (1995) Phosphorylation of the 26\u00a0kDa TNF precursor in monocytic cells and in transfected HeLa cells. J Inflamm 45:152\u2013160","journal-title":"J Inflamm"},{"key":"5591_CR35","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/emboj\/18.8.2119","volume":"18","author":"AD Watts","year":"1999","unstructured":"Watts AD, Hunt NH, Wanigasekara Y, Bloomfield G, Wallach D, Roufogalis BD et al (1999) A casein kinase I motif present in the cytoplasmic domain of members of the tumour necrosis factor ligand family is implicated in \u2018reverse signalling\u2019. EMBO J 18:2119\u20132126","journal-title":"EMBO J"},{"key":"5591_CR36","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1189\/jlb.0703343","volume":"75","author":"S Kirchner","year":"2004","unstructured":"Kirchner S, Boldt S, Kolch W, Haffner S, Kazak S, Janosch P et al (2004) LPS resistance in monocytic cells caused by reverse signaling through transmembrane TNF (mTNF) is mediated by the MAPK\/ERK pathway. J Leukoc Biol 75:324\u2013331","journal-title":"J Leukoc Biol"},{"key":"5591_CR37","doi-asserted-by":"crossref","unstructured":"Tansey MG, Wyss-Coray T (2008) Cytokines in CNS inflammation and disease. In: Lane TE, Carson M (eds) Central nervous system diseases and inflammation. Springer, Berlin","DOI":"10.1007\/978-0-387-73894-9_5"},{"key":"5591_CR38","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4049\/jimmunol.144.1.129","volume":"144","author":"KW Selmaj","year":"1990","unstructured":"Selmaj KW, Farooq M, Norton WT, Raine CS, Brosnan CF (1990) Proliferation of astrocytes in vitro in response to cytokines. A primary role for tumor necrosis factor. J Immunol 144:129\u2013135","journal-title":"J Immunol"},{"key":"5591_CR39","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000112150","volume":"13","author":"JE Merrill","year":"1991","unstructured":"Merrill JE (1991) Effects of interleukin-1 and tumor necrosis factoralpha on astrocytes, microglia, oligodendrocytes, and glial precursors in vitro. Dev Neurosci 13:130\u2013137","journal-title":"Dev Neurosci"},{"key":"5591_CR40","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0167-5699(99)01573-X","volume":"21","author":"JD Sedgwick","year":"2001","unstructured":"Sedgwick JD, Riminton DS, Cyster JG, Korner H (2001) Tumor necrosis factor: a master-regulator of leukocyte movement. Immunol Today 21:110\u2013113","journal-title":"Immunol Today"},{"key":"5591_CR41","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1152\/japplphysiol.01005.2001","volume":"92","author":"LR Leon","year":"2002","unstructured":"Leon LR (2002) Invited review: cytokine regulation of fever: studies using gene knockout mice. J Appl Physiol 92:2648\u20132655","journal-title":"J Appl Physiol"},{"key":"5591_CR42","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1126\/science.1067859","volume":"295","author":"EC Beattie","year":"2002","unstructured":"Beattie EC, Stellwagen D, Morishita W, Bresnahan JC, Ha BK, Von Zastrow M et al (2002) Control of synaptic strength by glial TNFalpha. Science 295:2282\u20132285","journal-title":"Science"},{"key":"5591_CR43","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1113\/expphysiol.2005.030734","volume":"90","author":"M Pickering","year":"2005","unstructured":"Pickering M, Cumiskey D, O\u2019Connor JJ (2005) Actions of TNF-alpha on glutamatergic synaptic transmission in the central nervous system. Exp Physiol 90:663\u2013670","journal-title":"Exp Physiol"},{"key":"5591_CR44","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/cercor\/bhg108","volume":"14","author":"H Golan","year":"2004","unstructured":"Golan H, Levav T, Mendelsohn A, Huleihel M (2004) Involvement of tumor necrosis factor alpha in hippocampal development and function. Cereb Cortex 14:97\u2013105","journal-title":"Cereb Cortex"},{"key":"5591_CR45","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.brainres.2004.11.014","volume":"1034","author":"JY Zou","year":"2005","unstructured":"Zou JY, Crews FT (2005) TNF alpha potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NF kappa B inhibition. Brain Res 1034:11\u201324","journal-title":"Brain Res"},{"key":"5591_CR46","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/0896-6273(88)90162-6","volume":"1","author":"DW Choi","year":"1988","unstructured":"Choi DW (1988) Glutamate neurotoxicity and diseases of the nervous system. Neuron 1:623\u2013634","journal-title":"Neuron"},{"key":"5591_CR47","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1074-7613(00)80252-6","volume":"4","author":"H Hsu","year":"1996","unstructured":"Hsu H, Huang J, Shu HB, Baichwal V, Goeddel DV (1996) TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 4:387\u2013396","journal-title":"Immunity"},{"key":"5591_CR48","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1074\/jbc.274.2.1156","volume":"274","author":"A Gross","year":"1999","unstructured":"Gross A, Yin XM, Wang K, Wei MC, Jockel J, Milliman C et al (1999) Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1\/Fas death. J Biol Chem 274:1156\u20131163","journal-title":"J Biol Chem"},{"key":"5591_CR49","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0165-5728(90)90105-V","volume":"30","author":"JC Goodman","year":"1990","unstructured":"Goodman JC, Robertson CS, Grossman RG, Narayan RK (1990) Elevation of tumor necrosis factor in head injury. J Neuroimmunol 30:213\u2013217","journal-title":"J Neuroimmunol"},{"key":"5591_CR50","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1084\/jem.170.2.607","volume":"170","author":"FM Hofman","year":"1989","unstructured":"Hofman FM, Hinton DR, Johnson K, Merrill JE (1989) Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med 170:607\u2013612","journal-title":"J Exp Med"},{"key":"5591_CR51","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1056\/NEJM199108153250704","volume":"325","author":"MK Sharief","year":"1991","unstructured":"Sharief MK, Hentges R (1991) Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 325:467\u2013472","journal-title":"N Engl J Med"},{"key":"5591_CR52","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1600-0404.1988.tb03663.x","volume":"78","author":"J Beck","year":"1988","unstructured":"Beck J, Rondot P, Catinot L, Falcoff E, Kirchner H, Wietzerbin J (1988) Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand 78:318\u2013323","journal-title":"Acta Neurol Scand"},{"key":"5591_CR53","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0165-5728(91)90073-G","volume":"32","author":"D Maimone","year":"1991","unstructured":"Maimone D, Gregory S, Arnason BGW, Reder AT (1991) Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J Neuroimmunol 32:67\u201374","journal-title":"J Neuroimmunol"},{"key":"5591_CR54","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ana.410230405","volume":"23","author":"KW Selmaj","year":"1988","unstructured":"Selmaj KW, Raine CS (1988) Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 23:339\u2013346","journal-title":"Ann Neurol"},{"key":"5591_CR55","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0165-5728(96)00075-6","volume":"68","author":"A Cre\u2032ange","year":"1996","unstructured":"Cre\u2032ange A, Be\u2032lec L, Clair B, Raphael JC, Gherardi RK (1996) Circulating tumor necrosis factor (TNF)-\u03b1 and soluble TNF-\u03b1 receptors in patients with Guillain\u2013Barre\u2032 syndrome. J Neuroimmunol 68:95\u201399","journal-title":"J Neuroimmunol"},{"key":"5591_CR56","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1212\/WNL.56.5.666","volume":"56","author":"S Misawa","year":"2001","unstructured":"Misawa S, Kuwabara S, Mori M, Kawagushi N, Yoshiyama Y, Hattori T (2001) Serum levels of tumor necrosis factor-\u03b1 in chronic inflammatory polyneuropathy. Neurology 56:666\u2013669","journal-title":"Neurology"},{"key":"5591_CR57","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/ana.410330606","volume":"33","author":"MK Sharief","year":"1993","unstructured":"Sharief MK, McLean B, Thompson EJ (1993) Elevated serum levels of tumor necrosis factor-\u03b1 in Guillain\u2013Barre\u2032 syndrome. Ann Neurol 33:591\u2013596","journal-title":"Ann Neurol"},{"key":"5591_CR58","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1085-9489.2006.00065.x","volume":"11","author":"F Terenghi","year":"2006","unstructured":"Terenghi F, Allaria S, Nobile-Orazio E (2006) Circulating levels of cytokines and their modulation by intravenous immunoglobulin in multifocal motor neuropathy. J Peripher Nerv Syst 11:67\u201371","journal-title":"J Peripher Nerv Syst"},{"key":"5591_CR59","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0165-5728(97)00238-5","volume":"84","author":"J Zhu","year":"1998","unstructured":"Zhu J, Mix E, Link H (1998) Cytokine production and the pathogenesis of experimental autoimmune neuritis and Guillain\u2013Barre\u2032 syndrome. J Neuroimmunol 84:40\u201352","journal-title":"J Neuroimmunol"},{"key":"5591_CR60","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/0923-2494(92)80040-R","volume":"143","author":"G Said","year":"1992","unstructured":"Said G, Hontebeyrie-Joskowicz M (1992) Nerve lesions induced by macrophage activation. Res Immunol 143:589\u2013599","journal-title":"Res Immunol"},{"key":"5591_CR61","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0165-5728(93)90178-2","volume":"45","author":"G Stoll","year":"1993","unstructured":"Stoll G, Jung S, Jander S, van der Meide P, Hartung HP (1993) Tumor necrosis factor-alpha in immune-mediated demyelination and Wallerian degeneration of the rat peripheral nervous system. J Neuroimmunol 45:175\u2013182","journal-title":"J Neuroimmunol"},{"key":"5591_CR62","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0304-3940(01)01877-8","volume":"306","author":"A Weishaupt","year":"2001","unstructured":"Weishaupt A, Bruck W, Hartung T, Toyka KV, Gold R (2001) Schwann cell apoptosis in experimental autoimmune neuritis of the Lewis rat and the functional role of tumor necrosis factor-\u03b1. Neurosci Lett 306:77\u201380","journal-title":"Neurosci Lett"},{"issue":"suppl. 35","key":"5591_CR63","first-page":"S134","volume":"22","author":"MD Magnano","year":"2004","unstructured":"Magnano MD, Robinson WH, Genovese MC (2004) Demyelination and inhibition of tumor necrosis factor (TNF). Clin Exp Rheumatol 22(suppl. 35):S134\u2013S140","journal-title":"Clin Exp Rheumatol"},{"key":"5591_CR64","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1212\/WNL.45.6_Suppl_6.S44","volume":"45","author":"KW Selmaj","year":"1995","unstructured":"Selmaj KW, Raine CS (1995) Experimental autoimmune encephalomyelitis: immunotherapy with anti-tumor necrosis factor antibodies and soluble tumor necrosis factor receptors. Neurology 45:S44\u2013S49","journal-title":"Neurology"},{"key":"5591_CR65","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1212\/WNL.47.6.1531","volume":"47","author":"BW Oosten van","year":"1996","unstructured":"van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW, von Blomberg BM et al (1996) Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal antitumor necrosis factor antibody cA2. Neurology 47:1531\u20131534","journal-title":"Neurology"},{"key":"5591_CR66","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1212\/WNL.53.3.457","volume":"53","author":"The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS\/MRI Analysis Group","year":"1999","unstructured":"The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS\/MRI Analysis Group (1999) TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 53:457\u2013465","journal-title":"Neurology"},{"key":"5591_CR67","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0165-5728(96)00183-X","volume":"72","author":"WE Klinkert","year":"1997","unstructured":"Klinkert WE, Kojima K, Lesslauer W, Rinner W, Lassmann H, Wekerle H (1997) TNFa receptor fusion protein prevents experimental autoimmune encephalomyelitis and demyelination in Lewis rats: an overview. J Neuroimmunol 72:163\u2013168","journal-title":"J Neuroimmunol"},{"issue":"12","key":"5591_CR68","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","volume":"44","author":"N Mohan","year":"2001","unstructured":"Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H et al (2001) Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 44(12):2862\u20132869","journal-title":"Arthritis Rheum"},{"issue":"5","key":"5591_CR69","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/art.21814","volume":"54","author":"IS Shin","year":"2006","unstructured":"Shin IS, Baer AN, Kwon HJ, Papadopoulos EJ, Siegel JN (2006) Guillain-Barr\u00e9 and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy. Arthritis Rheum 54(5):1429\u20131434","journal-title":"Arthritis Rheum"},{"issue":"9","key":"5591_CR70","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/ard.2006.066787","volume":"66","author":"I Simsek","year":"2007","unstructured":"Simsek I, Erdem H, Pay S, Sobaci G, Dinc A (2007) Optic neuritis occurring with anti-tumour necrosis factor alpha therapy. Ann Rheum Dis 66(9):1255\u20131258","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"5591_CR71","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1365-2036.2008.03882.x","volume":"29","author":"CW Lees","year":"2009","unstructured":"Lees CW, Ali AI, Thompson AI, Ho GT, Forsythe RO, Marquez L et al (2009) The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. Aliment Pharmacol Ther 29(3):286\u2013297","journal-title":"Aliment Pharmacol Ther"},{"key":"5591_CR72","doi-asserted-by":"crossref","unstructured":"Bernatsky S, Renoux C, Suissa S. Demyelinating events in rheumatoid arthritis after drug exposures. Ann Rheum Dis published online 23 Jul 2009; doi: 10.1136\/ard.2009.111500","DOI":"10.1136\/ard.2009.111500"},{"issue":"4","key":"5591_CR73","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/archneurol.2009.11","volume":"66","author":"P Lozeron","year":"2009","unstructured":"Lozeron P, Denier C, Lacroix C, Adams D (2009) Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch Neurol 66(4):490\u2013497","journal-title":"Arch Neurol"},{"issue":"10","key":"5591_CR74","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1212\/WNL.57.10.1885","volume":"57","author":"NL Sicotte","year":"2001","unstructured":"Sicotte NL, Voskuhl RR (2001) Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 57(10):1885\u20131888","journal-title":"Neurology"},{"key":"5591_CR75","first-page":"756","volume":"125","author":"E Muteis-Olivas","year":"2005","unstructured":"Muteis-Olivas E, P\u00e9rez-Garc\u00eda C, Roquer-Gonz\u00e1lez J, Maymo-Guarch J (2005) Esclerosis m\u00faltiple tras el tratamiento con anticuerpo anti-TNF-\u03b1. Med Clin (Barc) 125:756\u2013759","journal-title":"Med Clin (Barc)"},{"issue":"5","key":"5591_CR76","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/00042737-200605000-00021","volume":"18","author":"E Dubcenco","year":"2006","unstructured":"Dubcenco E, Ottaway CA, Chen DL, Baker JP (2006) Neurological symptoms suggestive of demyelination in Crohn\u2019s disease after infliximab therapy. Eur J Gastroenterol Hepatol 18(5):565\u2013566","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"4","key":"5591_CR77","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/01.mcg.0000155126.82171.32","volume":"39","author":"PJ Enayati","year":"2005","unstructured":"Enayati PJ, Papadakis KA (2005) Association of anti-tumor necrosis factor therapy with the development of multiple sclerosis. J Clin Gastroenterol 39(4):303\u2013306","journal-title":"J Clin Gastroenterol"},{"issue":"8","key":"5591_CR78","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1212\/01.WNL.0000158681.29117.8B","volume":"64","author":"C Richez","year":"2005","unstructured":"Richez C, Blanco P, Lagueny A, Schaeverbeke T, Dehais J (2005) Neuropathy resembling CIDP in patients receiving tumor necrosis factor-alpha blockers. Neurology 64(8):1468\u20131470","journal-title":"Neurology"},{"issue":"10","key":"5591_CR79","first-page":"2079","volume":"31","author":"P Richette","year":"2004","unstructured":"Richette P, Dieud\u00e9 P, Damiano J, Liot\u00e9 F, Orcel P, Bardin T (2004) Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis. J Rheumatol 31(10):2079\u20132081","journal-title":"J Rheumatol"},{"issue":"1","key":"5591_CR80","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/00054725-200401000-00004","volume":"10","author":"CW Thomas Jr","year":"2004","unstructured":"Thomas CW Jr, Weinshenker BG, Sandborn WJ (2004) Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn\u2019s disease. Inflamm Bowel Dis 10(1):28\u201331","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"5591_CR81","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/01.meg.0000250589.45984.b4","volume":"19","author":"K Vadikolias","year":"2007","unstructured":"Vadikolias K, Kouklakis G, Heliopoulos I, Argyropoulou P, Papanas N, Tzilonidou M et al (2007) Acute paraplegia after the initiation of anti-tumour necrosis factor-alpha therapy for Crohn\u2019s disease. Eur J Gastroenterol Hepatol 19(2):159\u2013162","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"6","key":"5591_CR82","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1365-2710.2006.00779.x","volume":"31","author":"HF Cay","year":"2006","unstructured":"Cay HF, Gungor HA, Sezer I, Kacar C, Balci N (2006) Adverse effect of TNF-alpha blocker? Demyelination in an ankylosing spondylitis patient: a case report. J Clin Pharm Ther 31(6):645\u2013648","journal-title":"J Clin Pharm Ther"},{"issue":"5","key":"5591_CR83","first-page":"1018","volume":"33","author":"J Jarand","year":"2006","unstructured":"Jarand J, Zochodne DW, Martin LO, Voll C (2006) Neurological complications of infliximab. J Rheumatol 33(5):1018\u20131020","journal-title":"J Rheumatol"},{"issue":"6","key":"5591_CR84","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s10067-005-0097-x","volume":"25","author":"M Tanno","year":"2006","unstructured":"Tanno M, Nakamura I, Kobayashi S, Kurihara K, Ito K (2006) New-onset demyelination induced by infliximab therapy in two rheumatoid arthritis patients. Clin Rheumatol 25(6):929\u2013933","journal-title":"Clin Rheumatol"},{"issue":"Suppl 6","key":"5591_CR85","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00415-008-6020-z","volume":"255","author":"A Winkelmann","year":"2008","unstructured":"Winkelmann A, Patejdl R, Wagner S, Benecke R, Zettl UK (2008) Cerebral MRI lesions and anti-tumor necrosis factor-alpha therapy. J Neurol 255(Suppl 6):109\u2013114","journal-title":"J Neurol"},{"issue":"2","key":"5591_CR86","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.cyto.2008.11.002","volume":"45","author":"A Fromont","year":"2009","unstructured":"Fromont A, De Seze J, Fleury MC, Maillefert JF, Moreau T (2009) Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. Cytokine 45(2):55\u201357","journal-title":"Cytokine"},{"issue":"5","key":"5591_CR87","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1155\/2005\/358658","volume":"19","author":"HJ Freeman","year":"2005","unstructured":"Freeman HJ, Flak B (2005) Demyelination-like syndrome in Crohn\u2019s disease after infliximab therapy. Can J Gastroenterol 19(5):313\u2013316","journal-title":"Can J Gastroenterol"},{"issue":"4","key":"5591_CR88","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1002\/mus.21051","volume":"38","author":"DR Hooper","year":"2008","unstructured":"Hooper DR, Tarnopolsky MA, Baker SK (2008) Lewis-Sumner syndrome associated with infliximab therapy in rheumatoid arthritis. Muscle Nerve 38(4):1318\u20131325","journal-title":"Muscle Nerve"},{"issue":"2","key":"5591_CR89","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s10067-006-0317-z","volume":"26","author":"MG Tektonidou","year":"2007","unstructured":"Tektonidou MG, Serelis J, Skopouli FN (2007) Peripheral neuropathy in two patients with rheumatoid arthritis receiving infliximab treatment. Clin Rheumatol 26(2):258\u2013260","journal-title":"Clin Rheumatol"},{"issue":"1","key":"5591_CR90","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jaad.2005.05.039","volume":"54","author":"SA Sukal","year":"2006","unstructured":"Sukal SA, Nadiminti L, Granstein RD (2006) Etanercept and demyelinating disease in a patient with psoriasis. J Am Acad Dermatol 54(1):160\u2013164","journal-title":"J Am Acad Dermatol"},{"issue":"5 Suppl 1","key":"5591_CR91","doi-asserted-by":"crossref","first-page":"S260","DOI":"10.1016\/j.jaad.2005.03.062","volume":"53","author":"CN Berthelot","year":"2005","unstructured":"Berthelot CN, George SJ, Hsu S (2005) Distal lower extremity paresthesia and foot drop developing during adalimumab therapy. J Am Acad Dermatol 53(5 Suppl 1):S260\u2013S262","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"5591_CR92","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1085-9489.2005.00053.x","volume":"10","author":"D Cocito","year":"2005","unstructured":"Cocito D, Bergamasco B, Tavella A, Poglio F, Paolasso I, Costa PC et al (2005) Multifocal motor neuropathy during treatment with infliximab. J Peripher Nerv Syst 10(4):386\u2013387","journal-title":"J Peripher Nerv Syst"},{"issue":"1","key":"5591_CR93","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/rheumatology\/keh439","volume":"44","author":"C Rodriguez-Escalera","year":"2005","unstructured":"Rodriguez-Escalera C, Belzunegui J, Lopez-Dominguez L, Gonzalez C, Figueroa M (2005) Multifocal motor neuropathy with conduction block in a patient with rheumatoid arthritis on infliximab therapy. Rheumatology (Oxford) 44(1):132\u2013133","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"5591_CR94","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1212\/01.WNL.0000142974.81103.95","volume":"63","author":"OC Singer","year":"2004","unstructured":"Singer OC, Otto B, Steinmetz H, Ziemann U (2004) Acute neuropathy with multiple conduction blocks after TNF alpha monoclonal antibody therapy. Neurology 63(9):1754","journal-title":"Neurology"},{"issue":"10","key":"5591_CR95","first-page":"2287","volume":"30","author":"SJ Jarrett","year":"2003","unstructured":"Jarrett SJ, Cunnane G, Conaghan PG, Bingham SJ, Buch MH, Quinn MA et al (2003) Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol 30(10):2287\u20132291","journal-title":"J Rheumatol"},{"key":"5591_CR96","unstructured":"FDA Arthritis Advisory Committee Briefing Document (2003) Efficacy and safety review: infliximab. FDA"},{"key":"5591_CR97","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1136\/ard.2005.043166","volume":"65","author":"MH Schiff","year":"2006","unstructured":"Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB et al (2006) Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 65:889\u2013894","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"5591_CR98","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2165\/00002018-200427050-00003","volume":"27","author":"D Khanna","year":"2004","unstructured":"Khanna D, McMahon M, Furst DE (2004) Safety of tumour necrosis factor-alpha antagonists. Drug Saf 27(5):307\u2013324","journal-title":"Drug Saf"},{"issue":"5","key":"5591_CR99","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1600-0404.1996.tb00004.x","volume":"93","author":"R Midgard","year":"1996","unstructured":"Midgard R, Gr\u00f8nning M, Riise T, Kv\u00e5le G, Nyland H (1996) Multiple sclerosis and chronic inflammatory diseases. A case-control study. Acta Neurol Scand 93(5):322\u2013328","journal-title":"Acta Neurol Scand"},{"issue":"6","key":"5591_CR100","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1177\/1352458508088936","volume":"14","author":"NM Nielsen","year":"2008","unstructured":"Nielsen NM, Frisch M, Rostgaard K, Wohlfahrt J, Hjalgrim H, Koch-Henriksen N et al (2008) Autoimmune diseases in patients with multiple sclerosis and their first-degree relatives: a nationwide cohort study in Denmark. Mult Scler 14(6):823\u2013829","journal-title":"Mult Scler"},{"issue":"3","key":"5591_CR101","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/ana.410330309","volume":"33","author":"AD Sadovnick","year":"1993","unstructured":"Sadovnick AD, Armstrong H, Rice GP, Bulman D, Hashimoto L, Paty DW et al (1993) A population-based study of multiple sclerosis in twins: update. Ann Neurol 33(3):281\u2013285","journal-title":"Ann Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-010-5591-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-010-5591-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-010-5591-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T07:11:07Z","timestamp":1685603467000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-010-5591-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,22]]},"references-count":101,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["5591"],"URL":"https:\/\/doi.org\/10.1007\/s00415-010-5591-7","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,22]]}}}